Xenon Pharmaceuticals Inc.
NASDAQ:XENE · NASDAQ Global Market
-$0.29 today
Vol 1.90M · Avg 1.16M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:XENE · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$383.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-4.70, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.5M | $0 | $0 -100.0% | $9.4M -48.8% | $18.4M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $2.5M -0.7% | $2.6M -98.5% | $167.5M | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $5.0M +293.6% | -$2.6M +98.5% | -$167.5M -1875.6% | $9.4M -48.8% | $18.4M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 66.1% | — | — | 100.0% +0.0pp | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $300.9M +43.0% | $210.4M +25.6% | $167.5M +58.4% | $105.8M +40.2% | $75.5M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $79.6M +15.6% | $68.9M +48.0% | $46.5M +41.9% | $32.8M +49.4% | $22.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $378.0M +36.6% | $276.7M +494.6% | $46.5M -66.4% | $138.6M +42.2% | $97.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $2.5M -0.7% | $2.6M -27.7% | $3.5M +152.0% | $1.4M +55.1% | $906.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$342.4M -45.2% | -$235.9M -12.0% | -$210.5M -64.8% | -$127.7M -63.6% | -$78.1M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -4564.7% | — | — | -1354.0% -930.5pp | -423.5% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$373.1M -33.6% | -$279.3M -30.5% | -$214.1M -65.7% | -$129.1M -63.5% | -$79.0M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -4974.3% | — | — | -1368.9% -940.5pp | -428.4% | 16.6% | 24.1% | 22.0% |
| Interest Income | $26.8M -36.0% | $41.9M +51.9% | $27.6M +217.0% | $8.7M +1769.7% | $466.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $28.2M -31.1% | $40.9M +30.3% | $31.4M +706.8% | $3.9M +3602.9% | $105.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$344.9M -44.7% | -$238.4M -30.5% | -$182.7M -45.9% | -$125.3M -58.8% | -$78.9M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -4598.6% | — | — | -1327.7% -899.8pp | -427.9% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $1.0M +124.8% | -$4.1M -1300.3% | -$292.0K -347.5% | $118.0K +2066.7% | -$6.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$345.9M -47.6% | -$234.3M -28.5% | -$182.4M -45.5% | -$125.4M -58.9% | -$78.9M | $4.9B | $4.8B | $4.7B |
| Net Margin | -4612.1% | — | — | -1328.9% -901.1pp | -427.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$4 -44.9% | -$3 -10.3% | -$3 -32.5% | -$2 -16.4% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$4 -44.9% | -$3 -10.3% | -$3 -32.5% | -$2 -16.4% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $79.3M +1.7% | $77.9M +16.5% | $66.9M +10.5% | $60.5M +38.8% | $43.6M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $79.3M +1.7% | $77.9M +16.5% | $66.9M +10.5% | $60.5M +38.8% | $43.6M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Centessa Pharmaceuticals plc
NASDAQ:CNTA
$6.16B
Scholar Rock Holding Corporation
NASDAQ:SRRK
$5.64B
Apogee Therapeutics, Inc.
NASDAQ:APGE
$5.44B
Legend Biotech Corporation
NASDAQ:LEGN
$5.44B
CG Oncology, Inc. Common stock
NASDAQ:CGON
$5.38B
Travere Therapeutics, Inc.
NASDAQ:TVTX
$5.06B
Celcuity Inc.
NASDAQ:CELC
$4.07B
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$2.69B
Zai Lab Limited
NASDAQ:ZLAB
$2.09B
Ascentage Pharma Group International
NASDAQ:AAPG
$403.00M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does XENE generate?
Xenon Pharmaceuticals Inc. (XENE) reported $7.50M of revenue in fiscal 2025.
Is XENE profitable?
Xenon Pharmaceuticals Inc. (XENE) reported -$345,910,000.00 of net income, with a net margin of -4612.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.